H
Hansjörg Riehm
Researcher at Hannover Medical School
Publications - 81
Citations - 9511
Hansjörg Riehm is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Acute lymphocytic leukemia & Childhood Acute Lymphoblastic Leukemia. The author has an hindex of 41, co-authored 81 publications receiving 9080 citations. Previous affiliations of Hansjörg Riehm include Boston Children's Hospital & Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
Jacques J.M. van Dongen,T Seriu,E. Renate Panzer-Grümayer,Andrea Biondi,M. J. Pongers-Willemse,Lilly Corral,Frank Stolz,Martin Schrappe,Giuseppe Masera,Willem Kamps,Helmuth Gadner,Elisabeth R. van Wering,Wolf-Dieter Ludwig,Giuseppe Basso,Marianne Ac de Bruijn,Giovanni Cazzaniga,Klaudia Hettinger,Anna van der Does-van den Berg,Wim C. J. Hop,Hansjörg Riehm,Claus R. Bartram +20 more
TL;DR: Monitoring patients with childhood ALL at consecutive time points gives clinically relevant insight into the effectiveness of treatment, and combined information on MRD from the first 3 months of treatment distinguishes patients with good prognoses from those with poor prognose, and this helps in decisions whether and how to modify treatment.
Journal ArticleDOI
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Martin Schrappe,Alfred Reiter,Wolf-Dieter Ludwig,Jochen Harbott,Martin Zimmermann,Wolfgang Hiddemann,Charlotte M. Niemeyer,Günter Henze,Andreas Feldges,Felix Zintl,Bernhard Kornhuber,Jörg Ritter,Karl Welte,Helmut Gadner,Hansjörg Riehm +14 more
TL;DR: The overall improvement over the results in ALL-BFM 86 (6-year EFS, 72%; P =. 001) was based on fewer recurrences among patients in the MRG with B-cell-precursor ALL, indicating an advantage of more condensed induction therapy.
Journal ArticleDOI
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke,Alfred Reiter,Martin Zimmermann,Helmut Gadner,Martin Stanulla,Michael Dördelmann,Lutz Löning,Rita Beier,Wolf-Dieter Ludwig,Richard Ratei,Jochen Harbott,Joachim Boos,Georg Mann,Felix Niggli,Andreas Feldges,Günter Henze,Karl Welte,Jörn-Dirk Beck,T. Klingebiel,Charlotte M. Niemeyer,Felix Zintl,U. Bode,Christian Urban,Helmut Wehinger,Dietrich Niethammer,Hansjörg Riehm,Martin Schrappe +26 more
TL;DR: Consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients, and compared without previous trial ALL-BFM 90, consistently favorable results were achieved.
Journal ArticleDOI
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.
Martin Schrappe,A. Reiter,Martin Zimmermann,Jochen Harbott,W.-D. Ludwig,Günter Henze,Helmut Gadner,E. Odenwald,Hansjörg Riehm +8 more
TL;DR: While it has proven so far to be impossible to improve the outcome for the small group of high risk patients, the number of recurrences could be effectively reduced for the large group of patients responding adequately to the prednisone in vivo sensitivity test.
Journal ArticleDOI
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000
Anja Möricke,M Zimmermann,A. Reiter,Günter Henze,André Schrauder,Helmut Gadner,W.-D. Ludwig,J. Ritter,Jochen Harbott,Georg Mann,T. Klingebiel,Felix Zintl,Charlotte M. Niemeyer,Bernhard Kremens,Felix Niggli,Dietrich Niethammer,Karl Welte,Martin Stanulla,E. Odenwald,Hansjörg Riehm,Martin Schrappe +20 more
TL;DR: The major findings derived from these ALL-BFM trials were that preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX.